Contents

Chapter 1. Introduction
1.1. History and present state of mass spectrometry 3
1.2. Mass spectrometry for clinical medicine 7
1.3. Structure of this work 9
References 10

Chapter 2. Basic theory of mass spectrometry
2.1. Introduction 15
2.2. Mass spectrum 16
2.3. Ionizations 18
2.3.1. Electron ionization 18
2.3.2. Chemical ionization 20
2.3.3. Field desorption 23
2.3.4. Desorption chemical ionization 23
2.3.5. Atmospheric pressure chemical ionization 24
2.3.6. Plasma desorption 24
2.3.7. Thermospray ionization 25
2.3.8. Fast atom bombardment 25
2.3.9. Secondary ion mass spectrometry 27
2.3.10. Electrospray ionization 28
2.3.11. Matrix-assisted laser desorption ionization 30
2.4. Mass analyzer 31
2.4.1. Magnetic sector 31
2.4.1.1. Principle of magnetic sector analyzer 31
2.4.1.2. Double-focusing mass spectrometer 32
2.4.2. Quadrupole mass filter 33
2.4.3. Time-of-flight (TOF) 35
2.4.4. Ion trap (IT) 37
2.4.5. Fourier transform (FT) 38
2.5. Negative ion mass spectrometry (NIMS) 40
2.6. High resolution mass spectrometry (HRMS) 42

2.6.1. Exact mass 42
2.6.2. Resolution 42
2.6.3. Calibration standards 44
2.7. Gas chromatography/mass spectrometry (GC/MS) 50
2.7.1. Interface 50
2.7.1.1. Direct coupling 51
2.7.1.2. Open-split coupling 51
2.7.1.3. One-stage jet separator 54
2.7.2. Selected ion monitoring (SIM) 54
2.7.3. Mass chromatography (MC) 55
2.8. Thin-layer chromatography/mass spectrometry (TLC/MS) 56
2.9. Liquid chromatography/mass spectrometry (LC/MS) 56
2.9.1. Thermospray ionization (TSI) LC/MS 57
2.9.2. Particle beam (PB) LC/MS 58
2.9.3. Atmospheric pressure chemical ionization (APCI) LC/MS 59
2.9.4. Continuous-flow FAB (CF-FAB) LC/MS and frit-FAB-LC/MS 60
2.9.5. Electrospray ionization (ESI) LC/MS 61
2.10. Capillary zone electrophoresis/mass spectrometry (CZE/MS) 62
2.11. Tandem mass spectrometry (MS/MS) 63
2.11.1. MS/MS 63
2.11.2 Collisional activation (CA) and collision-induced dissociation (CID) 66
2.11.3. Linked scan 66
2.11.3.1. Product ion scan 67
2.11.3.2. Precursor ion scan 67
2.11.3.3. Constant neutral loss scan 68
2.11.4. MS/MS/MS (MS^3) 68
References 69

Chapter 3. Procedures for MS analysis of clinically relevant compounds
3.1. Introduction 75
3.2. Organic acids 76
3.2.1. Extraction 76
3.2.1.1. Urine 76
3.2.1.2. Protein-containing fluids 79
3.2.2. GC/MS 79
3.2.2.1. Trimethylsilylation 79
3.2.2.2. *tert*-Butyldimethylsilylation 81

3.2.2.3. Methylation 82
3.2.2.4. Oximation 82
3.2.3. LC/MS 83
3.3. Short-chain fatty acids 86
3.3.1. Extraction 86
3.3.2. GC/MS 87
3.4. Volatile compounds 87
3.4.1. Extraction 87
3.4.2. GC/MS 91
3.5. Polyols 91
3.5.1. Extraction 91
3.5.2. GC/MS 92
3.5.3. LC/MS 94
3.6. Amines 95
3.6.1. Extraction 95
3.6.2. GC/MS 97
3.6.3. LC/MS 99
3.7. Prostaglandins 99
3.7.1. Extraction 99
3.7.1.1. Organic solvent extraction 100
3.7.1.2. Solid-phase extraction 100
3.7.1.3. Immunoaffinity extraction 103
3.7.2. Separation 104
3.7.3. GC/MS 104
3.7.4. LC/MS 106
3.8. Steroids 107
3.8.1. Extraction 107
3.8.2. Separation 108
3.8.3. Hydrolysis of conjugated steroids 109
3.8.4. GC/MS 109
3.8.5. LC/MS 110
3.9. Bile acids 111
3.9.1. Extraction 111
3.9.2. Separation 111
3.9.3. Hydrolysis of conjugated bile acids 112
3.9.4. GC/MS 113
3.9.5. LC/MS 114
3.9.6. FAB-MS 114
3.10. Amino acids 114
3.10.1. Extraction 115

3.10.2. GC/MS 115
3.10.3. FAB-MS 117
3.11. Peptides and proteins 119
3.11.1. Cleavage of proteins to peptides 119
3.11.2. FAB-MS 121
3.11.3. ESI-MS 125
3.11.4. MALDI-MS 129
3.12. Nucleic acid constituents 131
3.12.1. Extraction 131
3.12.2. Hydrolysis of nucleic acids 133
3.12.3. GC/MS 135
3.12.4. LC/MS 136
3.12.5. FAB-MS 137
3.12.6. ESI-MS 139
3.12.7. MALDI-MS 139
References 140

Chapter 4. Mass spectrometry in uremia
4.1. Introduction 155
4.2. Search for uremic toxins 156
4.3. Organic acids 157
4.3.1. Free organic acids 158
4.3.2. Protein-bound organic acids 163
4.4. Phenols 170
4.5. Polyols 174
4.6. Steroids 181
References 184

Chapter 5. Mass spectrometry in diabetes mellitus
5.1. Introduction 191
5.2. Altered metabolism in diabetic ketoacidosis 192
5.2.1. Organic acids 192
5.2.2. Ketones 200
5.3. Metabolism of volatiles 200
5.4. Polyol metabolism 201
5.5. Glycation of proteins 206
References 217

Chapter 6. Mass spectrometry in Parkinson's disease
6.1. Introduction 223

6.2. Metabolism of MPTP, a parkinsonism-producing compound 224
6.3. Tetrahydroisoquinoline (TIQ) as a possible endogenous MPTP-like compound 230
6.3.1. Discovery of TIQ in human parkinsonian brain 230
6.3.2. Parkinsonism caused by TIQ in primates 233
6.3.3. Metabolism of TIQ in the brain 235
6.3.4. Presence of TIQ in foods 238
6.3.5. Search for other TIQs in the brain 241
6.4. L-DOPA and catecholamine metabolism 244
References 247

Chapter 7. Mass spectrometry in hepatic diseases
7.1. Introduction 253
7.2. Bile acid metabolism 255
7.2.1. Inborn errors of bile acid metabolism 256
7.2.1.1. 3β-Hydroxy-Δ^5-C_{27}-steroid dehydrogenase deficiency 256
7.2.1.2. 3-Keto-Δ^4-steroid 5β-reductase deficiency 258
7.2.1.3. Cerebrotendinous xanthomatosis (CTX) 260
7.2.1.4. Peroxisomal disorders 261
7.2.2. Bile acids in acquired hepatic diseases 263
7.2.2.1. GC/MS 264
7.2.2.2. FAB-MS and LSIMS 271
7.2.2.3. LC/MS 275
7.3. Bile alcohol metabolism 275
7.4. Ammonia metabolism 280
7.5. Metabolism of volatiles 280
7.6. Organic acid metabolism 281
7.7. Search for toxins causing hepatic encephalopathy 284
References 286

Chapter 8. Mass spectrometry in disorders of organic acid metabolism
8.1. Introduction 293
8.2. Propionic acidemia 302
8.2.1. Clinical features 302
8.2.2. Metabolism 302
8.2.3. Diagnosis and analysis 304
8.2.4. Application of FAB-MS 309
8.3. Methylmalonic aciduria 310

8.3.1. Clinical features 310
8.3.2. Metabolism 311
8.3.3. Diagnosis and analysis 312
8.4. Isovaleric acidemia 314
8.4.1. Clinical features 314
8.4.2. Metabolism 315
8.4.3. Diagnosis and analysis 316
8.5. Glutaric aciduria type 1 317
8.5.1. Clinical features 317
8.5.2. Metabolism 319
8.5.3. Diagnosis 319
8.5.4. Application of FAB-MS 321
8.6. Glutaric aciduria type 2 322
8.6.1. Clinical features 322
8.6.2. Metabolism 322
8.6.3. Diagnosis and analysis 322
8.7. β-Ketothiolase deficiency (2-methylacetoacetic aciduria, 2-methyl-3-hydroxybutyric aciduria) 324
8.7.1. Clinical features 324
8.7.2. Metabolism 324
8.7.3. Diagnosis 325
8.8. 3-Methylcrotonylglycinuria (3-methylcrotonyl-CoA carboxylase deficiency) 326
8.8.1. Clinical features 326
8.8.2. Metabolism 326
8.8.3. Diagnosis 327
8.9. 3-Hydroxy-3-methylglutaric aciduria 327
8.9.1. Clinical features 327
8.9.2. Metabolism 329
8.9.3. Diagnosis 329
8.10. 2-Ketoadipic aciduria 330
8.10.1. Clinical features 330
8.10.2. Metabolism 330
8.10.3. Diagnosis 332
8.11. Phenylketonuria 334
8.11.1. Clinical features 334
8.11.2. Metabolism 334
8.11.3. Diagnosis and analysis 335
8.11.4. Recent research 336
8.12. Tyrosinemia type 1 336

8.12.1. Clinical features 337
8.12.2. Metabolism 338
8.12.3. Diagnosis and analysis 338
8.12.4. Prenatal diagnosis 339
8.13. Tyrosinemia type 2 341
8.13.1. Clinical features 341
8.13.2. Metabolism 341
8.13.3. Diagnosis 341
8.14. Alcaptonuria 341
8.14.1. Clinical features 341
8.14.2. Metabolism 342
8.14.3. Diagnosis 343
8.15. Pyroglutamic aciduria 343
8.15.1. Clinical features 343
8.15.2. Metabolism 343
8.15.3. Diagnosis 345
8.16. Maple syrup urine disease 345
8.16.1. Clinical features 345
8.16.2. Metabolism 346
8.16.3. Diagnosis and analysis 347
8.17. Dihydrolipoyl dehydrogenase deficiency 347
8.17.1. Clinical features 347
8.17.2. Metabolism 348
8.17.3. Diagnosis 349
8.18. Fumaric aciduria 349
8.18.1. Clinical features 349
8.18.2. Metabolism 350
8.18.3. Diagnosis 350
8.19. Glyceroluria 351
8.19.1. Clinical features 351
8.19.2. Metabolism 351
8.19.3. Diagnosis 351
8.20. 4-Hydroxybutyric aciduria 352
8.20.1. Clinical features 352
8.20.2. Metabolism 353
8.20.3. Diagnosis and analysis 354
8.21. 2-Hydroxyglutaric aciduria 354
8.21.1. Clinical features 354
8.21.2. Metabolism 354
8.21.3. Diagnosis 354

8.22. 2-Hydroxybutyric aciduria 355
8.22.1. Clinical features 355
8.22.2. Metabolism 355
8.22.3. Diagnosis 355
8.23. 3-Methylglutaconic aciduria 355
8.23.1. Clinical features 355
8.23.2. Metabolism 356
8.23.3. Diagnosis 356
8.24. Primary hyperoxaluria 356
8.24.1. Clinical features 356
8.24.2. Metabolism 357
8.24.3. Diagnosis and analysis 357
8.25. D-Glyceric aciduria 357
8.25.1. Clinical features 357
8.25.2. Metabolism 358
8.25.3. Diagnosis 358
8.26. Dihydropyrimidine dehydrogenase deficiency 358
8.26.1. Clinical features 358
8.26.2. Metabolism 358
8.26.3. Diagnosis 359
8.27. Multiple carboxylase deficiency 359
8.27.1. Clinical features 359
8.27.2. Metabolism 360
8.27.3. Diagnosis 361
8.28. Mevalonic aciduria 361
8.28.1. Clinical features 361
8.28.2. Metabolism 361
8.28.3. Diagnosis 362
8.29. Ornithine transcarbamylase deficiency 363
8.29.1. Clinical features 363
8.29.2. Metabolism 363
8.29.3. Diagnosis 364
8.29.4. Recent research 364
8.30. Dicarboxylic aciduria 365
8.30.1. Diagnosis 365
8.30.2. Inherited defects in mitochondrial β-oxidation 368
8.30.2.1. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency 368
8.30.2.2. Long-chain acyl-CoA dehydrogenase (LCAD) deficiency 369

8.30.2.3. Short-chain acyl-CoA dehydrogenase (SCAD) deficiency 369
8.30.2.4. Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency 369
8.30.2.5. Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency 370
8.30.2.6. Glutaric aciduria type 2 370
8.30.2.7. Carnitine palmitoyltransferase (CPT) I deficiency 370
8.30.2.8 Carnitine palmitoyltransferase (CPT) II deficiency 370
8.30.2.9. Carnitine transport defect 370
8.30.2.10. Carnitine/acylcarnitine translocase deficiency 371
8.30.2.11. 2,4-Dienoyl-CoA reductase deficiency 371
8.30.3. Peroxisomal disorders 371
8.30.4. Other causes of dicarboxylic aciduria 372
8.30.4.1. Jamaican vomiting sickness 372
8.30.4.2. Reye's syndrome 373
8.30.4.3. Glycogen storage disease type 1 and type 3 373
8.30.4.4. Medium-chain triglyceride milk and valproic acid 373
References 374

Subject index 385